Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells

Oncogene

Volumn 33, Issue 41, 2014, Pages 4932-4940

  El Gazzar, A ^a   Cai, X ^a   Reeves, R S ^a   Dai, Z ^a   Caballero Benitez, A ^a   McDonald, D L ^a   Vazquez, J ^a   Gooley, T A ^a   Sale, G E ^a   Spies, T ^a   Groh, V ^a  

^a USA   (United States)

Author keywords

angiogenesis; breast cancer; metastasis; NKG2D receptor; xenotransplant

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; CARRIER PROTEIN; HLA ANTIGEN CLASS 1; KLRK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; RAET1E PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DEVELOPMENT; FEMALE; HUMAN; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SELF STIMULATION; TUMOR DEVELOPMENT; TUMOR GROWTH; TUMOR PROMOTION; ANIMAL; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; MCF 7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCID MOUSE; SECONDARY; XENOGRAFT;

MUS;

ANIMALS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HETEROGRAFTS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RNA INTERFERENCE;

EID: 84921761124     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.435     Document Type: Article

References (21)

1. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944-5958.
2. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
3. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
4. Upshaw JL, Leibson PJ. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 2006; 18: 167-175.
5. Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121-138.
6. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007; 7: 737-744.
7. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-441.
8. Benitez AC, Dai Z, Mann HH, Reeves RS, Margineantu DH, Gooley TA et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci USA 2011; 108: 4081-4086.
9. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. miR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
10. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-1. Cytokine Growth Factor Rev 2006; 17: 305-323.
11. Kaufman SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.
12. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955-1962.
13. Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010; 70: 10121-10130.
14. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71: 2066-2076.
15. Lehner M, Gotz G, Proff J, Schaft N, Dorrie J, Full F et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 2012; 7: e31210.
16. Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ et al. Chimeric NKG2D CARexpressing T cell-mediated attack of human ovarian cancer Is enhanced by histone deacetylase Inhibition. Hum Gene Ther 2013; 24: 295-305.
17. Noel A, Simon N, Raus J, Foidart JM. Basement membrane components (matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen. Biochem Pharmacol 1992; 43: 1263-1267.
18. Jiang B-H, Liu L-Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19-65.
19. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009; 106: 3913-3918.
20. Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO et al. Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest 2010; 120: 4289-4302.
21. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumorassociated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-6884.